Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2013
11/07/2013WO2013165898A2 Compositions and methods for inhibiting resolvases
11/07/2013WO2013165854A1 Cyclic amine substituted heterocyclic cetp inhibitors
11/07/2013WO2013165800A1 2α-METHYL-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 (2AMD) OR 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 (2MD) SUPPORT SURVIVAL AND FUNCTION OF TRANSPLANTED ISLET CELLS IN TYPE 1 DIABETES
11/07/2013WO2013165796A1 Crystalline form of a pyridyl-piperazinyl hepatitis c virus inhibitor
11/07/2013WO2013165776A1 Anti-obesity properties of pterostilbene
11/07/2013WO2013165606A1 Modulators of the relaxin receptor 1
11/07/2013WO2013165592A1 Treatment of latent hiv infection
11/07/2013WO2013165591A1 β-GLUCAN IMMUNOTHERAPEUTIC METHODS
11/07/2013WO2013165577A1 Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation
11/07/2013WO2013165575A1 Fluorinated 2-amino-4-(benzylamino)phenylcarbamate derivatives
11/07/2013WO2013165481A1 Method and product for headache relief
11/07/2013WO2013165327A1 Pharmaceutical formulations comprising thiocolchicoside
11/07/2013WO2013165320A1 Treating cancer by increasing expression of socs6
11/07/2013WO2013165264A1 Anthelmintic compositions
11/07/2013WO2013165251A1 Cannabis plant isolate comprising /\9-tetrahydrocannabinol and a method for preparing such an isolate
11/07/2013WO2013165021A1 Oral formulation
11/07/2013WO2013164841A2 A method of treatment for acne and an anti-acne formulation
11/07/2013WO2013164839A2 Amorphous form of apixaban, process of preparation and compositions thereof
11/07/2013WO2013164838A1 Heterocyclic compounds and their use for treatment of diabetes, obesity or related disorders
11/07/2013WO2013164794A1 Crystalline forms of vilazodone hydrochloride
11/07/2013WO2013164790A1 L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
11/07/2013WO2013164773A1 Substituted pyrazole compounds as crac modulators
11/07/2013WO2013164769A1 Substituted pyridine compounds as crac modulators
11/07/2013WO2013164730A1 Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2.
11/07/2013WO2013164711A1 Anti-adherent formulation including a cationic or nonionic acrylate co-polymer
11/07/2013WO2013164683A1 Anti-cancer lead molecule
11/07/2013WO2013164671A1 Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
11/07/2013WO2013164636A1 Avermectin pour-on formulation with reduced withdrawal time
11/07/2013WO2013164620A1 New alfentanil composition for the treatment of acute pain
11/07/2013WO2013164617A1 New sufentanil composition for the treatment of acute pain
11/07/2013WO2013164593A1 Pyrrolobenzodiazepines
11/07/2013WO2013164592A1 Pyrrolobenzodiazepines
11/07/2013WO2013164561A1 Tramadol for treating depression
11/07/2013WO2013164559A1 Antiretroviral composition
11/07/2013WO2013164473A1 Pharmaceutical composition comprising abiraterone acetate
11/07/2013WO2013164402A1 Methods of improving mental or health conditions
11/07/2013WO2013164382A1 Aqueous, sterile vitamin formulation
11/07/2013WO2013164380A1 Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
11/07/2013WO2013164337A1 New compounds and new use
11/07/2013WO2013164323A1 Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease
11/07/2013WO2013164321A1 Pyrazole aminopyrimidine derivatives as lrrk2 modulators
11/07/2013WO2013164316A1 A delayed release drug formulation
11/07/2013WO2013164315A1 A delayed release drug formulation
11/07/2013WO2013164292A1 Indanyloxydihydrobenzofuranylacetic acids
11/07/2013WO2013164257A1 New formulation
11/07/2013WO2013164204A1 Tritoqualine for use in the treatment of cystic fibrosis
11/07/2013WO2013164061A1 Pyrrolotriazinone derivatives
11/07/2013WO2013163766A1 ANTIMICROBIAL COMPOSITIONS COMPRISING A HYALURONIC ACID BINDING PEPTIDE AND A β-LACTAM ANTIBIOTIC
11/07/2013WO2013163758A1 Methods for treating and diagnosing blinding eye diseases
11/07/2013WO2013163675A1 Substituted 3-haloallylamine inhibitors of ssao and uses thereof
11/07/2013WO2013135602A3 Combination therapy for the treatment of ovarian cancer
11/07/2013WO2013132208A8 Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine
11/07/2013WO2013125730A3 Cationic graft-copolymer for drug delivery system
11/07/2013WO2013119607A3 Modified release formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
11/07/2013WO2013114400A3 Compressed pharmaceutical compositions of atypical antipsychotics
11/07/2013WO2013114204A9 A method of using adenosine and dipyridamole for pharmacologic stress testing, with specific compositions, unit dosage forms and kits
11/07/2013WO2013095286A3 Synergistic combination comprising avermectins and a nsaid for tumor inhibition
11/07/2013WO2013061161A3 New combination therapies for treating neurological disorders
11/07/2013WO2002083860A9 Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer
11/07/2013US20130296829 Non-sedating antihistamine injection formulations and methods of use thereof
11/07/2013US20130296460 In situ bonds
11/07/2013US20130296443 System and method of trans-venous pre-aortic ganglion ablation
11/07/2013US20130296442 Lutein/zeaxanthin for glare protection
11/07/2013US20130296441 Anti-Obesity Properties of Pterostilbene
11/07/2013US20130296440 Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation
11/07/2013US20130296439 Stabilized tolterodine tartrate formulations
11/07/2013US20130296438 Methods and compositions for use with k-ras mediated disorders
11/07/2013US20130296437 Treatment of Depression
11/07/2013US20130296435 Method of enhancing hair growth
11/07/2013US20130296434 Formulations and methods for treating amyloidosis
11/07/2013US20130296433 Phosphorus binder composition for treatment of hyperphosphatemia
11/07/2013US20130296431 Guanidino acetic acid used as an animal food additive
11/07/2013US20130296430 Compositions and methods for treating autism and autism spectrum disorder
11/07/2013US20130296429 L-ornithine phenyl acetate and methods of making thereof
11/07/2013US20130296428 Reduction of risk of obesity
11/07/2013US20130296427 Neramexane for the treatment or prevention of tinnitus related with stress or acute hearing loss
11/07/2013US20130296426 Analgesic
11/07/2013US20130296424 Fatty acid treatment for cardiac patients
11/07/2013US20130296423 Pharmaceutical compositions comprising fesoterodine
11/07/2013US20130296419 Products containing polyphenol(s) and l-arginine
11/07/2013US20130296417 Theaflavin Compositions, Production, and Method to Control Physiological Disorders in Mammals
11/07/2013US20130296416 Selective inhibition of beta1- adrenergic receptors for the treatment of pediatric heart failure
11/07/2013US20130296414 1-Phenyl-2-Dimethylaminomethyl Cyclohexane Compounds And Therapies For Depressive Symptoms, Pain and Incontinence
11/07/2013US20130296413 N-desmethyl-doxepin and methods of using the same to treat sleep disorders
11/07/2013US20130296411 Use of Artemisinin for Treating Tumors Induced by oncogenic Viruses and for Treating Viral Infections
11/07/2013US20130296410 Oligonucleotide chelate complexes
11/07/2013US20130296407 Combination Therapy for Cancer
11/07/2013US20130296404 Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same
11/07/2013US20130296403 Targeting en2, pax2, and/or defb1 for treatment of prostate conditions
11/07/2013US20130296399 microRNA Biomarkers for Human Breast and Lung Cancer
11/07/2013US20130296398 Use of the phytocannabinoid cannabidiol (cbd) in combination with a standard anti-epileptic drug (saed) in the treatment of epilepsy
11/07/2013US20130296396 Compositions for delivery of therapeutics into the eyes and methods for making and using same
11/07/2013US20130296394 Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions
11/07/2013US20130296392 Methods for the treatment of overactive bladder
11/07/2013US20130296390 Method and compositions for enhancing the safety of orally administered magnesium alpha-lipoate
11/07/2013US20130296389 Fungicide Active Substance Combinations
11/07/2013US20130296387 Topical non-aqueous pharmaceutical formulations
11/07/2013US20130296386 Small molecule rnase inhibitors and methods of use
11/07/2013US20130296382 Non-nucleoside reverse transcriptase inhibitors
11/07/2013US20130296380 Novel Ureas for the Treatment and Prevention of Cancer
1 ... 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 ... 7860